Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia

Molly Memel, Adam M. Staffaroni, Ignacio Ilan‐Gala, J. García Castro, John Kornak, Carmela M. Tartaglia, Rowan Saloner, Anna M. VandeBunte, Emily W. Paolillo, Claire J. Cadwallader, Coty Chen, Maria Luisa Gorno‐Tempini, Malu Mandelli, Liana Apostolova, N. R. Graff-Radford, Irene Litvan, Ece Bayram, Peter Pressman, Toji Miyagawa, Ian R. Mackenzie, Jill Goldman, R. Ryan Darby, Brian S. Appleby, Len Petrucelli, Tania Gendron, Hilary W. Heuer, Leah K. Forseberg, Julio C. Rojas, Bradley F. Boeve, Nellie Brushaber, Kimiko Domoto‐Reilly, Nupur Ghoshal, Maria I. Lapid, Belén Pascual, Suzee Lee, Eliana Marisa Ramos, Vijay K. Ramanan, Rosa Rademakers, Katya Rascovsky, Alexander Pantelyat, Joseph C. Masdeu, Allison Snyder, Adam L. Boxer, Howard J. Rosen, Kaitlin B. CasalettoAlzheimer 2025 · DOI

TL;DR

This study reveals that while females with autosomal dominant frontotemporal dementia (ADFTD) show a "cognitive resilience" in early, asymptomatic stages, they experience steeper clinical declines once symptoms manifest compared to males. This suggests that plasma neurofilament light chain (NfL), a key biomarker, is a less reliable predictor of progression in asymptomatic females, highlighting the need for sex-specific approaches in FTD research and clinical care.

What Problem Does This Paper Address?

Frontotemporal dementia (FTD) is a neurodegenerative disease that affects cognition, behavior, and language, often striking individuals at a younger age than Alzheimer's disease. While sex differences are known to influence the presentation and progression of other neurodegenerative conditions like Alzheimer's, these differences in FTD, particularly in its genetically driven autosomal dominant forms (ADFTD), have not been comprehensively characterized. Understanding these sex-specific patterns is crucial for accurate diagnosis, personalized patient care, and the development of targeted therapies. This paper aims to fill this knowledge gap by longitudinally examining how sex influences the clinical trajectory of ADFTD.

Methods

The researchers employed a longitudinal study design, following 337 participants with ADFTD for up to six years. They utilized Linear Mixed-Effects (LME) models, a standard statistical technique for analyzing repeated measures data, to investigate how sex and disease stage (asymptomatic, mild behavioral/cognitive impairment (MBCI), or dementia) interact to influence cognitive function, functional status (measured by the CDR+NACC FTLD-SB score), and plasma neurofilament light chain (NfL) levels over time. NfL is a biomarker indicative of neuroaxonal damage. They also conducted post-hoc analyses to explore genotype-specific effects and the predictive utility of baseline NfL.

Datasets

The study utilized data from the ALLFTD (Autosomal-dominant Frontotemporal Lobar Degeneration) Consortium. This consortium comprises participants from 28 centers across the United States and Canada who carry pathogenic variants in one of the three most common genes associated with autosomal dominant FTD: MAPT, GRN, and C9orf72. The dataset includes annual clinical assessments and plasma samples collected over several years. No new benchmark datasets were introduced.

Key Insights and Ideas

  • "Cognitive Resilience" in Females: Females with ADFTD appear to exhibit a period of "cognitive resilience" in the early, asymptomatic stages. They maintain better cognitive and functional performance relative to their level of neurodegeneration (as indicated by NfL) compared to males.
  • Accelerated Decline Post-Symptom Onset: This resilience is followed by a more rapid decline in cognitive and functional abilities once symptoms manifest, suggesting a trade-off where the disease burden accumulates silently before a more precipitous decline.
  • NfL as a Sex-Dependent Biomarker: Plasma NfL is a strong prognostic marker for clinical progression in asymptomatic males. However, its predictive utility is significantly weaker in asymptomatic females, indicating that NfL alone may not be sufficient to predict disease trajectory in this group during the early stages.
  • Disease Stage is Key: The interaction between sex and disease stage is critical. Sex differences in clinical trajectories primarily emerge once individuals become symptomatic.
  • Potential for Sex-Specific Therapies: The findings underscore the importance of considering biological sex in the development of FTD therapies and diagnostic tools, as sex-specific biological pathways may influence disease manifestation and progression.

Key Results

  • Overall Trajectories: While there were no significant sex differences in longitudinal cognitive or functional trajectories when considering the entire cohort, females showed a more rapid increase in plasma NfL over time compared to males.
  • Asymptomatic Stage: In asymptomatic participants, females and males did not differ in cognitive, functional, or NfL trajectories. However, the relationship between baseline NfL and clinical outcomes was weaker in females, suggesting less predictive power for NfL in this group.
  • Symptomatic Stages: Once symptomatic (MBCI or dementia), females exhibited steeper declines in cognition and function compared to males. Females with dementia showed the steepest declines and greatest increases in NfL.
  • NfL Increase: Females showed a steeper increase in plasma NfL over the study duration (9.2 pg/mL annually) compared to males (1.3 pg/mL annually).
  • Baseline NfL: Females with dementia had significantly higher baseline NfL concentrations than males with dementia.

Limitations and Future Work

The authors acknowledge several limitations:

  • Lack of Pathological Data: The study relies on clinical and biomarker data, not direct pathological confirmation, which is the gold standard for FTD diagnosis.
  • Small Sample Sizes in Subgroups: Genotype-specific analyses and analyses of participants with MBCI or dementia had smaller sample sizes, potentially limiting the power to detect subtle differences.
  • Limited Diversity: The cohort was predominantly White, limiting the generalizability of findings to more diverse populations. Factors like ethnicity, race, and socioeconomic status can influence comorbid vascular pathology and disease progression.
  • Focus on Cognitive/Functional Aspects: The study did not systematically examine sex differences in behavioral symptoms, which is a focus of a separate, related manuscript.
  • Informant Bias: While sensitivity analyses were conducted, the gender of the study informant was unknown for a significant portion of the sample, which could introduce bias in symptom reporting.

Future work should focus on:

  • Larger, Diverse Cohorts: Replicating these findings in larger and more ethnically diverse populations.
  • Investigating Biological Mechanisms: Delving into the underlying biological mechanisms driving these sex differences, such as neuroimmune processes, hormonal changes (e.g., menopause), and X chromosome biology.
  • Understanding Gender vs. Sex: Further exploring the interplay of social and cultural gender roles with biological sex in FTD diagnosis and progression.
  • Clinical Trial Design: Incorporating sex as a critical factor in the design and interpretation of clinical trials for FTD.

Summary updated

Abstract

Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.
BibTeX
@inproceedings{memel2025sex,
  author = {Molly Memel and Adam M. Staffaroni and Ignacio Ilan‐Gala and J. García Castro and John Kornak and Carmela M. Tartaglia and Rowan Saloner and Anna M. VandeBunte and Emily W. Paolillo and Claire J. Cadwallader and Coty Chen and Maria Luisa Gorno‐Tempini and Malu Mandelli and Liana Apostolova and N. R. Graff-Radford and Irene Litvan and Ece Bayram and Peter Pressman and Toji Miyagawa and Ian R. Mackenzie and Jill Goldman and R. Ryan Darby and Brian S. Appleby and Len Petrucelli and Tania Gendron and Hilary W. Heuer and Leah K. Forseberg and Julio C. Rojas and Bradley F. Boeve and Nellie Brushaber and Kimiko Domoto‐Reilly and Nupur Ghoshal and Maria I. Lapid and Belén Pascual and Suzee Lee and Eliana Marisa Ramos and Vijay K. Ramanan and Rosa Rademakers and Katya Rascovsky and Alexander Pantelyat and Joseph C. Masdeu and Allison Snyder and Adam L. Boxer and Howard J. Rosen and Kaitlin B. Casaletto},
  title = {{Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia}},
  booktitle = {Alzheimer},
  year = {2025},
  doi = {10.1002/alz.14630},
}
Figure